These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 12819187

  • 1. WY-14,643-mediated promotion of hepatocarcinogenesis in connexin32-wild-type and connexin32-null mice.
    Moennikes O, Stahl S, Bannasch P, Buchmann A, Schwarz M.
    Carcinogenesis; 2003 Sep; 24(9):1561-5. PubMed ID: 12819187
    [Abstract] [Full Text] [Related]

  • 2. Lack of phenobarbital-mediated promotion of hepatocarcinogenesis in connexin32-null mice.
    Moennikes O, Buchmann A, Romualdi A, Ott T, Werringloer J, Willecke K, Schwarz M.
    Cancer Res; 2000 Sep 15; 60(18):5087-91. PubMed ID: 11016633
    [Abstract] [Full Text] [Related]

  • 3. Overexpression of glutamine synthetase is associated with beta-catenin-mutations in mouse liver tumors during promotion of hepatocarcinogenesis by phenobarbital.
    Loeppen S, Schneider D, Gaunitz F, Gebhardt R, Kurek R, Buchmann A, Schwarz M.
    Cancer Res; 2002 Oct 15; 62(20):5685-8. PubMed ID: 12384525
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Differences between the promoting activities of the peroxisome proliferator WY-14,643 and phenobarbital in rat liver.
    Cattley RC, Popp JA.
    Cancer Res; 1989 Jun 15; 49(12):3246-51. PubMed ID: 2566380
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Hepatocarcinogenesis in female mice with mosaic expression of connexin32.
    Moennikes O, Buchmann A, Willecke K, Traub O, Schwarz M.
    Hepatology; 2000 Sep 15; 32(3):501-6. PubMed ID: 10960441
    [Abstract] [Full Text] [Related]

  • 8. Colocalized alterations in connexin32 and cytochrome P450IIB1/2 by phenobarbital and related liver tumor promoters.
    Neveu MJ, Babcock KL, Hertzberg EL, Paul DL, Nicholson BJ, Pitot HC.
    Cancer Res; 1994 Jun 15; 54(12):3145-52. PubMed ID: 8205533
    [Abstract] [Full Text] [Related]

  • 9. Tumor promotion in liver of mice with a conditional Cx26 knockout.
    Marx-Stoelting P, Mahr J, Knorpp T, Schreiber S, Templin MF, Ott T, Buchmann A, Schwarz M.
    Toxicol Sci; 2008 Jun 15; 103(2):260-7. PubMed ID: 18308698
    [Abstract] [Full Text] [Related]

  • 10. The effect of connexin32 null mutation on hepatocarcinogenesis in different mouse strains.
    Moennikes O, Buchmann A, Ott T, Willecke1 K, Schwarz M.
    Carcinogenesis; 1999 Jul 15; 20(7):1379-82. PubMed ID: 10383916
    [Abstract] [Full Text] [Related]

  • 11. Transgenic disruption of gap junctional intercellular communication enhances early but not late stage hepatocarcinogenesis in the rat.
    Hokaiwado N, Asamoto M, Ogawa K, Shirai T.
    Toxicol Pathol; 2005 Jul 15; 33(6):695-701. PubMed ID: 16243774
    [Abstract] [Full Text] [Related]

  • 12. Role of connexin32 and beta-catenin in tumor promotion in mouse liver.
    Schwarz M, Wanke I, Wulbrand U, Moennikes O, Buchmann A.
    Toxicol Pathol; 2003 Jul 15; 31(1):99-102. PubMed ID: 12597453
    [Abstract] [Full Text] [Related]

  • 13. The peroxisome proliferator WY-14,643 promotes hepatocarcinogenesis caused by endogenously generated oxidative DNA base modifications in repair-deficient Csbm/m/Ogg1-/- mice.
    Trapp C, Schwarz M, Epe B.
    Cancer Res; 2007 Jun 01; 67(11):5156-61. PubMed ID: 17545594
    [Abstract] [Full Text] [Related]

  • 14. Sequential histologic study of rat liver during peroxisome proliferator [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]-acetic acid (Wy-14,643)-induced carcinogenesis.
    Rao MS, Lalwani ND, Reddy JK.
    J Natl Cancer Inst; 1984 Oct 01; 73(4):983-90. PubMed ID: 6592391
    [Abstract] [Full Text] [Related]

  • 15. Effect of the tumor promoter phenobarbital on the pattern of global gene expression in liver of connexin32-wild-type and connexin32-deficient mice.
    Stahl S, Ittrich C, Marx-Stoelting P, Köhle C, Ott T, Buchmann A, Schwarz M.
    Int J Cancer; 2005 Jul 20; 115(6):861-9. PubMed ID: 15751032
    [Abstract] [Full Text] [Related]

  • 16. Tumor formation in liver of conditional β-catenin-deficient mice exposed to a diethylnitrosamine/phenobarbital tumor promotion regimen.
    Rignall B, Braeuning A, Buchmann A, Schwarz M.
    Carcinogenesis; 2011 Jan 20; 32(1):52-7. PubMed ID: 21047994
    [Abstract] [Full Text] [Related]

  • 17. Selective pressure during tumor promotion by phenobarbital leads to clonal outgrowth of beta-catenin-mutated mouse liver tumors.
    Aydinlik H, Nguyen TD, Moennikes O, Buchmann A, Schwarz M.
    Oncogene; 2001 Nov 22; 20(53):7812-6. PubMed ID: 11753661
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of mutant frequencies of chemically induced tumors and normal tissues in lambda/cII transgenic mice.
    Mirsalis JC, Shimon JA, Johnson A, Fairchild D, Kanazawa N, Nguyen T, de Boer J, Glickman B, Winegar RA.
    Environ Mol Mutagen; 2005 Nov 22; 45(1):17-35. PubMed ID: 15605353
    [Abstract] [Full Text] [Related]

  • 19. Oxidants from nicotinamide adenine dinucleotide phosphate oxidase are involved in triggering cell proliferation in the liver due to peroxisome proliferators.
    Rusyn I, Yamashina S, Segal BH, Schoonhoven R, Holland SM, Cattley RC, Swenberg JA, Thurman RG.
    Cancer Res; 2000 Sep 01; 60(17):4798-803. PubMed ID: 10987289
    [Abstract] [Full Text] [Related]

  • 20. Quantitative analysis of the time-dependent development of glucose-6-phosphatase-deficient foci in the livers of mice treated neonatally with diethylnitrosamine.
    Moore MR, Drinkwater NR, Miller EC, Miller JA, Pitot HC.
    Cancer Res; 1981 May 01; 41(5):1585-93. PubMed ID: 7214332
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.